HPV clinical
Answered by
University of Washington
Seattle - WA
This forum does not cover AIDS/HIV issues. This forum is for questions and support regarding STD issues such as:
Chlamydia, Crabs (pubic lice scabies),
Gonorrhea, Hepatitis (viral),
Herpes, HPV, Molluscum Contagiosum, PID, Rectal Infections, Syphilis, Trichomonas, Warts,
Yeast Infection.
IMPORTANT
This forum is limited to questions about STDs other than HIV/AIDS. For questions about HIV prevention, or if you have general questions about safe sex (e.g., condoms, how to protect yourself from HIV and STDs), please visit the
HIV Prevention and Safe Sex Forum
Some of the most common types of questions concern the risk of HIV or STD after a particular sexual exposure, and about symptoms that might or might not be due to HIV. If your question is along these lines, please visit the
HIV Prevention and Safe Sex Forum.
Secondly, if antibody could not serve as an assessment tool, couldn't they follow the viral load of HPV 16 for evidence of clearance?
Thanks for your help.
Tests for antibody and viral load are completely different tests.
Thanks
"For those already infected, the clinical trials suggested the (Gardasil) vaccine can cut the onset of pre-cancerous lesions, though the 27 per cent reduction achieved doesn't technically qualify for the rigid statistical nod of approval. "
http://www.smh.com.au/news/cancer/big-win-on-cancer/2006/02/08/1139379562005.html.?page=2
Most likely there is at least partial protection after the second shot. But everybody for sure should have the third dose.